Alexion Announces Launch of Alexion Charitable Foundation and Calls for Grantees
February 27 2020 - 8:30AM
Business Wire
- Ahead of Rare Disease Day, new support
becomes available to the rare community -
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the
launch of the Alexion Charitable Foundation to provide further
support for the rare disease community and for local communities
which the company serves. The key components of the Foundation are
the Rare Belonging™ and Local Needs Grants focus areas. Rare
Belonging seeks to advance emotional well-being and educational
opportunities, and provide relief for critical needs, especially
for those living with or affected by a rare disease. The Foundation
seeks eligible, disease-agnostic nonprofit organizations to help
create and execute programs aligned with these priorities.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20200227005210/en/
“Alexion understands that the impact of living with a rare
disease goes far beyond the disease itself. It affects families,
caregivers and has broad reaching implications in terms of mental
health, education, and even job security,” said Rana Strellis,
Senior Vice President, Global Culture and Corporate Social
Responsibility at Alexion. “Through Rare Belonging, we hope to work
with eligible, disease-agnostic nonprofits to help alleviate some
of these challenges.”
Rare Belonging, to be funded through grants made by the
Foundation to other, disease-agnostic nonprofit organizations, is
designed to benefit people affected by any of the 6,000 diseases
identified in the Global Genes' RARE list,1 including patients,
their families and caregivers by providing funding for:
- Mental health counseling: Connecting the rare disease
community with mental health professionals, supporting mental
health tracks at rare disease conferences and providing related
assistance.
- Education and job skills: Providing funding for
educational needs for children and young adults and career
reskilling for adults newly diagnosed with a rare disease.
- Transportation and accommodations: Reducing the
financial burden of traveling to important social, educational and
advocacy opportunities, as well as to doctor appointments,
hospitals, infusion centers, clinical trials and medical centers of
excellence.
- Critical needs: Providing financial assistance in times
of critical need, such as natural disasters or significant,
unplanned expenses.
The Foundation, through its Local Needs Grants, will also
contribute a portion of its funding to organizations in the
communities where Alexion has a major presence and that align with
the mission of the Foundation. Local Needs Grants are focused on
helping organizations that serve disadvantaged or disenfranchised
people, with a focus on advancing emotional well-being, educational
opportunities and the cause of diversity in society and critical
institutions.
To learn more about eligibility requirements and/or to apply for
a grant from the Alexion Charitable Foundation, visit
https://alexion.com/our-commitment/alexion-charitable-foundation.
About the Alexion Charitable Foundation The Alexion
Charitable Foundation, a nonprofit* foundation, is organized and
operated exclusively for charitable and educational purposes. Its
mission is to offer promise and cultivate a sense of belonging —
particularly for people affected by a rare disease — through
initiatives that advance emotional well-being, educational
opportunities and economic relief. The Alexion Charitable
Foundation is separate from Alexion Pharmaceuticals, Inc. and its
corporate giving, patient support programs and direct engagement
with various patient organizations. The Alexion Charitable
Foundation makes grants on a disease-agnostic basis and does not
provide funding for the costs of clinical care to treat rare
diseases, such as the cost of prescription medicines. To learn
more, visit
https://alexion.com/our-commitment/alexion-charitable-foundation.
*The Alexion Charitable Foundation has applied for and is
currently awaiting confirmation of its 501(c)(3) status.
About Alexion Alexion is a global biopharmaceutical
company focused on serving patients and families affected by rare
diseases through the discovery, development and commercialization
of life-changing medicines. As the global leader in complement
biology and inhibition for more than 20 years, Alexion has
developed and commercializes two approved complement inhibitors to
treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and
atypical hemolytic uremic syndrome (aHUS), as well as the first and
only approved complement inhibitor to treat anti-acetylcholine
receptor (AchR) antibody-positive generalized myasthenia gravis
(gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion
also has two highly innovative enzyme replacement therapies for
patients with life-threatening and ultra-rare metabolic disorders,
hypophosphatasia (HPP) and lysosomal acid lipase deficiency
(LAL-D). In addition, the company is developing several
mid-to-late-stage therapies, including a copper-binding agent for
Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for
rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D
inhibitor as well as several early-stage therapies, including one
for light chain (AL) amyloidosis, a second oral Factor D inhibitor
and a third complement inhibitor. Alexion focuses its research
efforts on novel molecules and targets in the complement cascade
and its development efforts on the core therapeutic areas of
hematology, nephrology, neurology, metabolic disorders and
cardiology. Headquartered in Boston, Massachusetts, Alexion has
offices around the globe and serves patients in more than 50
countries. This press release and further information about Alexion
can be found at: www.alexion.com.
[ALXN-G]
1 | https://globalgenes.org/rare-list/
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200227005210/en/
Media Megan Goulart, 857-338-8634 Senior Director,
Corporate Communications
Alexion Pharmaceuticals (NASDAQ:ALXN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Alexion Pharmaceuticals (NASDAQ:ALXN)
Historical Stock Chart
From Sep 2023 to Sep 2024